Video

Safety, efficacy of KPI-121 0.25% for DED treatment

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|AAO

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of dry eye disease in patients enrolled in four trials.

See more AAO coverage

Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
Researchers awarded $2.7 million NIH grant to study retinal connections in RP
December 14th 2024

Researchers awarded $2.7 million NIH grant to study retinal connections in RP

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Study finds increased air pollution leads to surge in daily eye clinic visits
December 9th 2024

Study finds increased air pollution leads to surge in daily eye clinic visits

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

BostonSight publishes pilot study on PROSE scleral lenses as a drug delivery system for cyclosporine in dry eye treatment
December 6th 2024

BostonSight publishes pilot study on PROSE scleral lenses as a drug delivery system for cyclosporine in dry eye treatment

Cambium Bio completes funding to help advance dry eye disease treatment
December 5th 2024

Cambium Bio completes funding to help advance dry eye disease treatment

© 2024 MJH Life Sciences

All rights reserved.